| Literature DB >> 29250977 |
Anna Sola1, Laura Saenz Del Burgo1,2, Jesús Ciriza1,2, Rosa Maria Hernandez1,2, Gorka Orive1,2, Jorge Martin Cordero3, Priscila Calle3, Jose Luis Pedraz1,2, Georgina Hotter1,3.
Abstract
Epithelial to mesenchymal transition (EMT) has emerged as a key process in the development of renal fibrosis. In fact, EMT-derived fibroblasts contribute to the progression of chronic renal disease. In addition, anti-inflammatory M2 macrophages have exhibited a great influence on renal fibrosis. However, because of the high impact that the inputs of different environmental cytokines have on their phenotype, macrophages can easily lose this property. We aim to known if microencapsulated macrophages on M2-inducing alginate matrices could preserve macrophage phenotype and thus release factors able to act on epithelial cells to prevent the epithelial differentiation towards mesenchymal cells. We reproduced an in vitro model of EMT by treating adipose-derived stem cells with all-trans retinoic acid (ATRA) and induced their transformation toward epithelia. Dedifferentiation of epithelial cells into a mesenchymal phenotype occurred when ATRA was retired, thus simulating EMT. Results indicate that induction of M2 phenotype by IL-10 addition in the alginate matrix produces anti-inflammatory cytokines and increases the metabolic activity and the viability of the encapsulated macrophages. The released conditioned medium modulates EMT and maintains healthy epithelial phenotype. This could be used for in vivo cell transplantation, or alternatively as an external releaser able to prevent epithelial to mesenchymal transformation for future anti-fibrotic therapies.Entities:
Keywords: Cell microencapsulation; alginate; biomaterials; drug delivery; mesenchymal stem cells; renal failure
Mesh:
Substances:
Year: 2018 PMID: 29250977 PMCID: PMC6058712 DOI: 10.1080/10717544.2017.1413449
Source DB: PubMed Journal: Drug Deliv ISSN: 1071-7544 Impact factor: 6.419
Primer sequence.
| Gen | Source | Primer sequence |
|---|---|---|
| PAX2 (NM.011037.4) | Applied biosystems | Taqman Gene Expression Assay ID: Mm01217939_m1 |
| Aquaporina 1 (NM 007472.2) | Invitrogen | Reverse: GGGACTTCCTCTCCCTCAAA |
| Megalina (NM 001081088.1) | Invitrogen | Reverse: TGCTGGCTTGGAAGACTTTT |
Figure 1.(A) Morphology of microencapsulated Raw 264.7 cells at 4×106 cell/ml density under the inverted optical microscopy (left panel) and fluorescence microscopy after calcein/ethidium staining the day after encapsulation. The last image on the right corresponds to the merge image of both staining. Scale bar 200 μm. (B) Metabolic activity of encapsulated Raw 264.7 cells measured by the Cell Counting Kit 8 (CCK-8) assay for three weeks. N = 3. Data are means ± SD..
Figure 2.Induction of the anti-inflammatory M2 state of Raw 264.7 cells with or without microencapsulation. IL-10 and TNF-alpha production of Raw 264.7 cells determined by ELISA when 2 ng/ml of IL-10 is added into the culture media before encapsulation (A), in the alginate matrix (B), or without encapsulation but with IL-10 addition once (C). N = 3. Data are means ± SD, *p < .05 versus control basal levels.
Figure 3.Fluorescence microscope images of encapsulated Raw 264.7 cells stained with calcein AM (live cells, column 1) and ethidium homodimer (dead cells, column 2) at day 4 post-encapsulation. Control capsules (A), 2 ng/ml of IL-10 added into the culture media before encapsulation (B), or 2 ng/ml of Il-10 added in the alginate matrix (C). Column 3 represents the merged image from columns 1 and 2.
Figure 4.Effect of anti-inflammatory M2 supernatants on epithelial to mesenchymal transition markers. Phase contrast images and immunofluorescence of phalloidin, vimentin, megalin, and cytokeratin18 (CK-18) in ASC untreated (Control); ASC treated with ATRA for 7 days (ATRA); below ATRA withdrawal for 24 h (−ATRA); ATRA withdrawal followed by anti-inflammatory macrophages conditioned medium for 24 h following (−ATRA + M2CM)), Phase-contrast images and phalloidin staining of F-actin cytoskeleton (red) nuclei (blue). In addition, immunofluorescence of vimentin (green), nuclei (blue). Immunocytochemistry of CK18, nuclei counterstained with hematoxylin. Immunofluorescence of megalin (green), nuclei (blue). Images were obtained by phase contrast microscopy, immunofluorescence, and immunocytochemistry. Magnification 20×.
Figure 5.qRT-PCR analysis of PAX-2, MEGALIN, and AQUAPORIN-1. Total RNA was extracted from ASC untreated (Control); ASC treated with ATRA for 7 days (ATRA), below ATRA withdrawal for 24 h (−ATRA), treated with anti-inflammatory macrophages conditioned medium for 24 h following ATRA withdrawal (−ATRA + M2CM). N = 4. Data are means ± SD. *p < .05 versus untreated. +p < .05 versus ATRA.